coronaviru
diseas
infecti
diseas
caus
sever
acut
respiratori
syndrom
coronaviru
droplet
contact
main
mean
transmiss
sinc
first
case
appear
wuhan
china
decemb
outbreak
gradual
spread
nationwid
accord
offici
data
releas
chines
health
commiss
number
newli
diagnos
patient
declin
epidem
gradual
control
although
patient
mild
symptom
good
prognosi
infect
patient
develop
sever
die
multipl
organ
complic
pathogenesi
infect
human
remain
unclear
immun
function
strong
defens
invas
pathogen
current
specif
antivir
drug
viru
articl
review
immunolog
chang
coronavirus
like
sar
mer
viral
pneumonia
similar
combin
publish
literatur
potenti
pathogenesi
infer
treatment
recommend
give
highdos
intraven
immunoglobulin
lowmolecularweight
heparin
anticoagul
therapi
sever
type
patient
propos
coronavirus
cov
top
news
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
merscov
outbreak
saudi
arabia
south
korea
sinc
new
coronaviru
occur
wuhan
hubei
provinc
quickli
spread
across
whole
china
countri
date
februari
approxim
infecti
patient
confirm
caus
death
need
urgent
viral
infect
identif
intervent
earli
possibl
although
nucleic
acid
test
play
utmost
part
detect
viral
genom
sequenc
overhypersensit
depend
sampl
may
lead
degre
falseposit
falseneg
clinic
despit
sever
type
research
conduct
practic
treatment
possibl
medicin
consensu
recommend
antivir
medicin
confirm
immun
system
play
vital
role
defens
sarscov
mer
infect
immun
chang
patient
sar
mer
influenza
especi
chang
peripher
blood
lymphocyt
subset
contribut
understand
characterist
diagnosi
monitor
prevent
treatment
diseas
acut
phase
sarscov
infect
rapid
reduct
lymphocyt
peripher
blood
mainli
lymphocyt
observ
lymphocyt
decreas
loss
lymphocyt
preced
even
abnorm
chang
chest
xray
oneyear
followup
sar
patient
cell
recov
rapidli
diseas
recoveri
period
lymphocyt
return
normal
within
month
onset
memori
cell
return
normal
year
onset
wherea
cell
count
includ
total
lymphocyt
cell
cell
naiv
cell
still
lower
healthi
control
assum
viral
infect
lymphocytopenia
peripher
blood
due
lymphocyt
sequestr
firstli
increas
lymphocyt
recoveri
new
cell
produc
thymu
lymphocyt
recircul
peripher
blood
tissu
organ
sarsspecif
igg
antibodi
produc
late
acut
stage
week
gradual
increas
cours
diseas
sustain
exist
igg
make
patient
acquir
immun
function
infect
recov
patient
high
sustain
level
proteinspecif
neutral
antibodi
respons
may
play
import
role
determin
diseas
outcom
igg
level
mild
patient
significantli
higher
sever
patient
cours
diseas
progress
patient
may
accompani
increas
level
peak
earli
stage
recoveri
show
rapid
increas
earli
acut
stage
gradual
decreas
progress
diseas
base
find
propos
treat
diseas
lowdos
glucocorticoid
less
week
earli
stage
diseas
symptom
sever
patient
well
control
differ
effect
highdos
glucocorticoid
describ
literatur
previous
unknown
coronaviru
merscov
isol
patient
caus
high
mortal
rate
familybas
hospitalbas
outbreak
similar
sever
acut
respiratori
syndrom
coronaviru
sarscov
genom
structur
two
virus
similar
singlestrand
positivesens
rna
virus
enter
host
cell
merscov
sarscov
attach
differ
receptor
dipeptidyl
peptidas
angiotensinconvert
enzym
respect
besid
clinic
manifest
merscov
infect
like
sarscov
rang
asymptomat
infect
sever
pneumonia
acut
respiratori
distress
syndrom
septic
shock
multiorgan
failur
result
death
though
clinic
pathogenesi
explain
clearli
retrospect
studi
compar
patient
south
korea
suggest
decreas
number
peripher
lymphocyt
lymphopenia
absolut
lymphocyt
count
lower
thrombocytopenia
platelet
count
lower
high
crp
level
could
predict
pneumonia
develop
progress
respiratori
failur
earli
cours
diseas
result
support
evid
report
min
et
al
wherea
noteworthi
lymphopenia
mer
infect
signific
sar
patient
research
found
except
immunosuppress
state
concomit
infect
age
predictor
concern
merscov
cell
respons
within
two
week
onset
symptom
acut
phase
besid
proinflammatori
cytokinechemokin
secret
interleukin
il
cxc
motif
chemokin
cxcl
high
frequenc
merscovreact
cell
observ
patient
severemoder
ill
detect
humor
cell
respons
convalesc
phase
magnitud
cell
respons
greatli
augment
result
indic
ineffici
control
invad
merscov
bring
robust
inflammatori
ctl
respons
play
vital
role
clear
viru
pbmc
obtain
day
ill
onset
show
strong
specif
tcell
respons
merscov
protein
role
cytotox
lymphocyt
ctl
protect
mhv
member
beta
coronaviru
group
sarscov
merscov
viru
clearanc
also
demonstr
anim
experiment
model
zhao
j
et
al
found
convalesc
phase
neutral
antibodi
titer
measur
vitro
predict
serum
protect
abil
infect
mice
correl
cell
respons
experi
cell
phenotyp
effector
memori
cell
virusspecif
cell
popul
half
effector
cell
half
cell
persist
gradual
increas
lymphocyt
respons
symptom
onset
mer
patient
may
requir
effect
immun
respons
merscov
whether
ctl
turnov
effect
cell
provid
still
need
research
differ
disappear
mer
sar
influenza
pandem
incorpor
season
strain
howev
influenza
pandem
rel
high
mortal
rate
compar
influenza
viru
iav
influenza
b
viru
ibv
usual
cove
season
strain
influenza
genom
contain
segment
capabl
antigen
drift
shift
make
small
nucleotid
mutat
exchang
genom
segment
respect
due
characterist
novel
antigen
never
exist
human
popul
make
season
epidem
possibl
manifest
infect
rang
subclin
symptom
signific
malais
fever
myalgia
rhinorrhea
progress
acut
hypoxemia
acut
respiratori
distress
extrapulmonari
present
like
gastrointestin
neurolog
cardiac
dysfunct
also
describ
review
albeit
pandem
viru
infect
host
immun
pattern
incomplet
character
earli
respons
period
increas
plasma
level
especi
may
marker
critic
ill
anoth
studi
map
healthi
volunt
cell
respons
influenza
infect
demonstr
influenzaspecif
cell
correl
diseas
protect
influenza
challeng
human
howev
kristin
gi
mohn
et
al
stimul
pbmc
acut
convalesc
patient
suggest
significantli
lower
frequenc
influenzaspecif
compar
tcell
acut
patient
high
level
cell
direct
conserv
core
antigen
convalesc
patient
consid
lack
enough
sampl
size
studi
design
whether
discrep
lymphocyt
subgroup
domin
differ
period
infect
explor
lymphocyt
count
link
diseas
sever
noteworthi
season
influenza
infect
peripher
lymphocyt
count
lymphocyt
subset
show
signific
correl
prognosi
sever
ill
studi
compar
iav
ibv
patient
healthi
subject
elev
serum
level
decreas
nk
count
relat
patient
infect
review
literatur
virus
respiratori
infect
like
sarscov
merscov
influenza
viru
caus
period
outbreak
death
histopatholog
examin
show
common
characterist
diffus
alveolar
damag
edemat
lung
lesion
pneumonia
besid
examin
viru
infect
demonstr
capabl
viru
replic
effici
upper
lower
respiratori
tract
associ
mild
moder
clinic
sign
patholog
chang
though
merscov
infect
rhesu
macaqu
could
detect
transient
lymphocyt
cell
reduct
first
day
inocul
jiang
gu
et
al
hypothes
mark
lymphocyt
cell
declin
weaken
immun
system
aggrav
sar
infect
respiratori
tract
summari
viru
replic
distribut
associ
immun
respons
contribut
progress
infecti
diseas
chang
peripher
lymphocyt
chang
transit
lymphocyt
subgroup
may
provid
new
thought
pathogenesi
infect
base
publish
literatur
clinic
observ
patient
propos
reason
hypothes
pathogenesi
infect
human
viru
might
pass
mucou
membran
especi
nasal
larynx
mucosa
enter
lung
respiratori
tract
earli
common
symptom
infect
fever
cough
viru
may
enter
peripher
blood
lung
caus
viremia
viru
would
attack
target
organ
express
lung
heart
renal
gastrointestin
tract
detect
fecal
sampl
like
viru
enter
blood
lung
travel
blood
intestin
support
hypothesi
dawei
wang
et
al
found
median
time
symptom
onset
ard
day
specul
way
viru
begin
second
attack
caus
patient
condit
aggrav
around
day
onset
infect
process
white
blood
cell
count
peripher
blood
earli
stage
diseas
normal
slightli
low
lymphopenia
observ
patient
specul
b
lymphocyt
reduct
may
occur
earli
diseas
may
affect
antibodi
product
patient
sever
type
patient
lymphocyt
significantli
reduc
specul
lymphocyt
patient
might
gradual
decreas
diseas
progress
mechan
signific
lymphocyt
reduct
sever
type
patient
remain
unclear
besid
inflammatori
factor
associ
diseas
mainli
contain
significantli
increas
also
contribut
aggrav
diseas
around
day
onset
nonsurvivor
higher
level
neutrophil
ddimer
blood
urea
nitrogen
creatinin
survivor
base
assumpt
clinic
phase
divid
three
viremia
phase
acut
phase
pneumonia
phase
recoveri
phase
immun
function
patient
acut
phase
pneumonia
phase
effect
basic
diseas
viru
effect
suppress
enter
recoveri
phase
patient
older
immun
impair
state
combin
basic
diseas
hypertens
diabet
immun
system
effect
control
viru
acut
phase
pneumonia
phase
patient
becom
sever
critic
type
mention
hypothesi
cell
b
cell
reduc
inflammatori
cytokin
ddimer
continu
increas
sever
type
patient
figur
enhanc
immun
function
patient
inhibit
format
inflammatori
factor
storm
propos
follow
two
therapeut
measur
specif
antivir
drug
treatment
current
treatment
diseas
mainli
focus
symptomat
treatment
oxygen
therapi
inflammatori
factor
lymphocyt
subset
recommend
monitor
diseas
suggest
ivig
low
molecular
weight
heparin
lmwh
anticoagul
therapi
could
given
earli
possibl
cell
b
cell
inflammatori
cytokin
ddimer
show
follow
trend
lymphocyt
b
lymphocyt
peripher
blood
significantli
lower
inflammatori
cytokin
increas
significantli
coagul
paramet
ddimer
increas
abnorm
chest
ct
indic
expans
lung
lesion
recommend
highdos
ivig
g
per
kg
weight
per
day
could
given
day
interrupt
storm
inflammatori
factor
earli
stage
enhanc
immun
function
random
control
clinic
trial
ivig
patient
sever
infect
initi
nct
although
ivig
shown
efficaci
treatment
patient
influenza
sar
need
clinic
data
patient
evid
lmwh
anticoagul
therapi
especi
recommend
earli
stage
diseas
infect
common
caus
dissemin
intravascular
coagul
inflamm
infect
factor
lead
excess
activ
coagul
observ
clinic
patient
sever
type
may
develop
dissemin
intravascular
coagul
dic
unpublish
data
patient
sever
type
ischem
chang
may
occur
finger
toe
figur
anticoagul
therapi
recommend
patient
ddimer
valu
time
higher
normal
upper
limit
except
patient
anticoagul
contraind
recommend
dose
lmwh
per
kg
weight
per
h
subcutan
inject
atleast
day
clinician
close
monitor
indic
laboratori
examin
patient
alert
side
effect
anticoagul
treatment
conclus
current
treatment
patient
sever
type
critic
type
key
control
rise
number
death
recommend
earli
initi
ivig
lmwh
anticoagul
therapi
effect
improv
prognosi
sever
critic
type
patient
figur
describ
optim
time
initi
ivig
lmwh
anticoagul
therapi
well
possibl
trend
cell
b
cell
inflammatori
cytokin
ddimer
therapi
immunerel
research
need
help
us
understand
pathogenesi
guid
treatment
diseas
improv
prognosi
